KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Total Debt (2016 - 2025)

Eli Lilly (LLY) has disclosed Total Debt for 17 consecutive years, with $42.5 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Debt rose 26.33% year-over-year to $42.5 billion, compared with a TTM value of $42.5 billion through Dec 2025, up 26.33%, and an annual FY2025 reading of $42.5 billion, up 26.33% over the prior year.
  • Total Debt was $42.5 billion for Q4 2025 at Eli Lilly, roughly flat from $42.5 billion in the prior quarter.
  • Across five years, Total Debt topped out at $42.5 billion in Q3 2025 and bottomed at $15.9 billion in Q3 2022.
  • Average Total Debt over 5 years is $24.9 billion, with a median of $19.5 billion recorded in 2023.
  • The sharpest move saw Total Debt dropped 7.01% in 2022, then soared 55.34% in 2023.
  • Year by year, Total Debt stood at $16.9 billion in 2021, then fell by 3.83% to $16.2 billion in 2022, then skyrocketed by 55.34% to $25.2 billion in 2023, then surged by 33.37% to $33.6 billion in 2024, then grew by 26.33% to $42.5 billion in 2025.
  • Business Quant data shows Total Debt for LLY at $42.5 billion in Q4 2025, $42.5 billion in Q3 2025, and $39.9 billion in Q2 2025.